Compare LSTA & RKTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LSTA | RKTO |
|---|---|---|
| Founded | 1980 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.9M | 18.9M |
| IPO Year | 2000 | 2018 |
| Metric | LSTA | RKTO |
|---|---|---|
| Price | $1.20 | $0.32 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 108.7K | ★ 266.1K |
| Earning Date | 11-24-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.42 | ★ 29.69 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $35,283,868.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 56.90 | N/A |
| 52 Week Low | $0.96 | $0.33 |
| 52 Week High | $5.07 | $1.19 |
| Indicator | LSTA | RKTO |
|---|---|---|
| Relative Strength Index (RSI) | 56.44 | 19.74 |
| Support Level | $1.23 | N/A |
| Resistance Level | $1.28 | $0.77 |
| Average True Range (ATR) | 0.12 | 0.04 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 56.18 | 3.92 |
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.
Rocket One Inc is focused on developing and commercializing infrastructure for the orbital economy, including next-generation nanomagnetic AI chip technology designed for radiation-tolerant, energy-constrained environments such as low-Earth orbit, deep-space platforms, and defense systems. The company also intends to pursue opportunities related to nano-launch systems and nanosatellite deployment. In addition, its biotechnology operations, conducted through a wholly owned subsidiary, include development programs such as HT-001, HT-KIT, HT-ALZ, and a GDNF-based metabolic program.